Furthermore, CDK7 inhibition synergises with p53-activating agents, including 5-fluorouracil, and induces apoptosis in colorectal cancer cells [88], while combining CDK12/13 inhibition with DNA-damaging chemotherapy, including cisplatin, irinotecan, doxorubicin and with the PARP inhibitor olaparib was shown to augment anticancer activity in TNBC cells [83]. The gene discussed is CDK7; the disease is colorectal cancer.